Table 2. Factors affecting transdermal transport and bioavailability. Psychotropic medication and transdermal

patches Medical specialties such as general practice, palliative care and endocrinology frequently use transdermal formulations for pain relief, smoking cessation and hormone replacement, but the use of psychotropics as transdermal patches is less studied and underinvestigated. Advances in enhancing transdermal drug delivery have led to treatment options for various psychiatric and neuropsychiatric conditions. Conditions such as depression, attention deficit hyperactivity disorder (ADHD), Parkinson’s disease and dementia benefit from long-acting formulations Inhibitors,research,lifescience,medical due to the nature of the symptom relief required and this can be achieved through

constant plasma levels of medication against episodic peaks. TDS may be of particular Inhibitors,research,lifescience,medical use in patients who are unable or unwilling to take oral or intramuscular medicines. Offering patients another formulation also facilitates control and choice over their treatment. An appropriately administered patch which is visible and potentially easy to monitor offers clinicians reassurance in patients who are noncompliant that a medicine is administered without the Inhibitors,research,lifescience,medical need for invasive and often injurious intramuscular injections when given under restraint. Table 3 summarizes Inhibitors,research,lifescience,medical the psychotropics that are currently approved by the US Food and Drug Administration (FDA) and the UK Medicine http://www.selleckchem.com/products/pci-32765.html healthcare Regulatory Authority (MHRA). Table 3. Summary of various psychotropic drugs used as transdermal systems. Dementia Dementia is a chronic condition that has significant impact on an individual’s health and social care [Harada and Vanderplas, 2006]. The cost of dementia care in Inhibitors,research,lifescience,medical the UK is expected to rise to approximately £28 billion by 2018 [All Party Parliamentary

Group on Dementia, 2011]. In a time of increasing financial constraints, the demand to implement a more efficient approach to the delivery of community-based healthcare is increasing. In patients receiving antidementia therapies for longer periods at adequate doses there is a greater chance of slowing or delaying the progression of cognitive decline, leading to fewer admissions to nursing homes and reduced healthcare costs [Harada and Vanderplas, mafosfamide 2006]. However, misunderstanding complex titration schedules can result in people with dementia receiving subtherapeutic doses [Bernabei and Lage, 2008]. Medications featuring less frequent dosing schemes, such as extended-wear transdermal patches, are capturing the interest of providers and healthcare purchasers. Rivastigmine is a cholinesterase inhibitor used for treating Alzheimer’s disease and dementia associated with Parkinson’s disease. It is the only antidementia drug currently available as a transdermal formulation.